More Articles

Diabetes and high blood pressure generics in Europe Reports | Posted 21/03/2014

Generics contribute value to the European Union (EU), according to a presentation by Mr Victor Lino Mendonça given at the International Generic Pharmaceutical Alliance (IGPA)’s 16th Annual Conferen...

Long-acting G-CSF lipegfilgrastim launched in UK Biosimilars/News | Posted 21/03/2014

Teva UK, a subsidiary of generics giant Teva Pharmaceutical Industries (Teva) announced on 24 February 2014 the launch of its long-acting granulocyte colony-stimulating factor (G‑CSF) Lonquex (lipe...

Indian generics makers face US recalls Generics/News | Posted 21/03/2014

Indian generics makers are once again coming under US Food and Drug Administration (FDA) scrutiny.

Generics contribution to availability of essential medicines Generics/Research | Posted 14/03/2014

The creation of Essential Medicines Lists (EMLs) within country healthcare systems is promoted by the World Health Organization (WHO) in order to improve the availability and use of medicines consi...

How safe is Zarzio after five years’ clinical experience? Biosimilars/Research | Posted 14/03/2014

The first filgrastim biosimilar was approved in Europe in 2008, prompting Dr Pere Gascón and co-authors to review the evidence relating to the efficacy and safety of biosimilar Zarzio (filgrastim)...

Brand-name drugs also cut healthcare costs Generics/General | Posted 14/03/2014

Generics are often given all the praise when it comes to cutting costs for patients and payers, but, according to a piece in Forbes, brand-name drugs also cut healthcare costs.

Amgen starts another phase III trial for biosimilar adalimumab Biosimilars/News | Posted 14/03/2014

US biotechnology giant Amgen has started recruiting for a phase III clinical trial of its biosimilar adalimumab in patients suffering from plaque psoriasis, according to the US clinical trials webs...

FDA approves generic osteoporosis drug Generics/News | Posted 14/03/2014

FDA announced on 4 March 2014 that it had approved Teva Pharmaceutical Industries (Teva’s) generic version of Eli Lilly’s osteoporosis drug Evista (raloxifene).